Inspiration Healthcare Group (IHC) Fair Value & Analysis
Healthcare · GB · Market cap 23.0M GBX
Fair value as of: Jun 25, 2026
Analysis
Inspiration Healthcare Group (IHC) currently trades at p0.2250, while our model-based Fair Value estimate is p0.0800 — implying the stock looks roughly 64.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Inspiration Healthcare Group plc designs, manufactures, and sells medical technology products worldwide. The company offers products for acute care comprising developmental and intensive care, monitoring, neonatal, obstetrics, operating theatres, pain management and developmental, respiratory, resus, thermo regulatory, and transport areas. It also offers infusion therapies and products, such as ambulatory infusion pumps, administration sets, accessories, patient infusion management systems, and medical infusion devices for acute pain management, obstetrics, parenteral nutrition, palliative care, oncology, immunoglobulin therapy, antibiotic infusion, and other, as well as manufactures and sells pneumatic ventilators. The company serves the hospital sector. Inspiration Healthcare Group plc was incorporated in 1998 and is based in Croydon, the United Kingdom.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Inspiration Healthcare Group (IHC) undervalued?
What is the fair value of IHC?
What is the quality score of IHC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.